文献速递胸部神经MR

整合列线图预测EGFR-TKI联合颅内放疗的颅内无进展生存期:一项多中心研究

Integrated nomogram for predicting intracranial progression-free survival with EGFR-TKI combined with cranial radiotherapy: a multicenter study.
PubMed 文献 · Eur Radiol · 2025-10-31

本研究纳入三家医院409例接受EGFR-TKI联合颅内放疗的EGFR突变非小细胞肺癌脑转移患者,整合临床特征、Lung-molGPA评分和MRI影像组学构建列线图预测颅内无进展生存期。整合列线图预测性能优于单模态方法,训练队列AUC为0.888,内部验证为0.897,两个外部验证队列分别为0.883和0.903。

要点

  • 整合临床、Lung-molGPA和MRI影像组学的列线图可预测EGFR突变NSCLC脑转移患者iPFS。
  • 放疗方式是iPFS的独立预后因素,整合列线图AUC在外部验证队列达0.883/0.903。
  • 脑转移体积和一线治疗状态也是iPFS的独立临床预测因素。

核心结论

  • 整合列线图为预测EGFR突变NSCLC脑转移患者接受EGFR-TKI联合颅内放疗后的iPFS提供了稳健工具,预测性能优于单模态方法。

研究设计与样本

  • 多中心研究,纳入三家医院409例合格患者,分析临床数据、Lung-molGPA评分和治疗前MRI影像组学特征,分为训练、内部验证和两个独立外部验证队列,采用LASSO算法筛选影像组学特征并构建列线图。

诊断标准与关键数值

  • 整合列线图预测iPFS的AUC:训练队列0.888,内部验证队列0.897,两个外部验证队列分别为0.883和0.903;最终选取12个影像组学特征构建影像组学标签;总体队列中位iPFS为15.07个月。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: Development and validation of a nomogram integrating clinical characteristics, Lung Molecular Graded Prognostic Assessment (Lung-molGPA) score, and MRI-based radiomics to predict intracranial progression-free survival (iPFS) in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) patients with brain metastases (BM) receiving concurrent EGFR-tyrosine kinase inhibitor (EGFR-TKI) and cranial radiotherapy.

MATERIALS AND METHODS: This study enrolled 409 eligible patients from three major hospitals. Clinical data, Lung-molGPA scores, and pre-treatment MRI-derived radiomic features were analyzed. Cluster analysis was used to evaluate the discriminative ability and intergroup consistency of radiomic features. Patients were divided into training, internal validation, and two independent external validation cohorts. Radiomic features were selected using the least absolute shrinkage and selection operator (LASSO) algorithm, and nomograms were developed and validated to predict iPFS. Model performance was evaluated using receiver operating characteristic (ROC) curves, concordance indexes (C-indexes), and decision curve analysis (DCA).

RESULTS: The median iPFS of the overall cohort was 15.07 months. Independent clinical predictors of iPFS encompassed BM volume, radiotherapy modality, and first-line treatment status. Cluster analysis revealed that radiomic features could be stably classified into two distinct groups with strong intergroup consistency. Twelve radiomic features were ultimately selected to develop the radiomic signature. The integrated nomogram demonstrated superior predictive performance over single-modality approaches, with area under the curve (AUC) values of 0.888 (training cohort), 0.897 (internal validation), and 0.883/0.903 in two external validation cohorts.

CONCLUSION: The integrated nomogram provides a robust tool for predicting iPFS in EGFR-mutant NSCLC patients with BM.

KEY POINTS: Question Currently, effective predictive tools for intracranial progression-free survival following combined epidermal growth factor receptor tyrosine kinase inhibitor and cranial radiotherapy treatment are lacking. Findings The integrated nomogram provided superior prediction of intracranial progression-free survival and radiotherapy modality was identified as a key independent prognostic factor. Clinical relevance This non-invasive model enhances individualized therapy planning and optimizes cranial radiotherapy approaches, advancing precision care for non-small cell lung cancer patients with brain metastases.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Qi H, Hou Y, Zheng Z, et al. Integrated nomogram for predicting intracranial progression-free survival with EGFR-TKI combined with cranial radiotherapy: a multicenter study. Eur Radiol. 2025. PMID: 41174041. doi:10.1007/s00330-025-12105-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。